2023/02/28 by Malte Hasle Nielsen, Matthew P. Gillum, Niels Vrang +4
Biochemistry, Genetics and Molecular Biology · Medicine · #Fibroblast Growth Factor Research #Kruppel-like factors research #Liver Disease Diagnosis and Treatment
paper · doi:10.1152/ajpgi.00157.2022
openalex publication_date 2023/02/28 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
It is unclear if long-acting FGF21 analogs have antifibrotic efficacy in NASH. We therefore profiled the clinically relevant FGF21 analog PF-05231023 in a translational diet-induced obese and biopsy-confirmed mouse model of NASH. We found PF-05231023 to exert hepatoprotective effects as indicated by notable improvements in plasma markers and histological hallmarks of NASH, including improved fibrosis stage. Collectively, the present study supports the continued exploration of long-acting FGF21 analogs for the treatment of NASH and other fibrotic diseases.